An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)

• Status: Completed
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with obesity (considerably overweight).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide

Criteria

Inclusion Criteria:

• Patients who are obese (considerably overweight) based on body mass index.

Exclusion Criteria:

• Patients with serious or unstable current or past medical conditions